Spots Global Cancer Trial Database for monoclonal
Every month we try and update this database with for monoclonal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | NCT01242943 | Patients With C... | 131I-L19SIP Rad... | 18 Years - 75 Years | Philogen S.p.A. | |
| L19TNFα in Patients With Advanced Solid Tumors | NCT01253837 | Solid Tumors Colorectal Canc... | L19TNFa | 18 Years - | Philogen S.p.A. | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC) | NCT01124812 | Non Small Cell ... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer | NCT01240720 | Cancer | 131I-F16SIP Rad... | 18 Years - | Philogen S.p.A. | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| Study of Factors Regulating Mast Cell Proliferation | NCT00044122 | Mastocytosis Monoclonal Bone Marrow Tryptase | 1 Day - 80 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) | NCT00593944 | Chronic Lymphoc... | MDX-1342 | 18 Years - | Bristol-Myers Squibb | |
| Study of Factors Regulating Mast Cell Proliferation | NCT00044122 | Mastocytosis Monoclonal Bone Marrow Tryptase | 1 Day - 80 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of Factors Regulating Mast Cell Proliferation | NCT00044122 | Mastocytosis Monoclonal Bone Marrow Tryptase | 1 Day - 80 Years | National Institutes of Health Clinical Center (CC) | ||
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | NCT00006436 | Lymphoma, AIDS-... Lymphoma, Large... | Rituximab Filgrastim EPOCH | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) | NCT00593944 | Chronic Lymphoc... | MDX-1342 | 18 Years - | Bristol-Myers Squibb | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors | NCT01125085 | Brain Metastase... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin | NCT00982111 | Non Small Cell ... | Pemetrexed Cisplatin Necitumumab | 18 Years - | Eli Lilly and Company | |
| L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | NCT02076620 | Advanced Solid ... Sarcoma, Breast... | L19TNFα Doxorubicin | 18 Years - | Philogen S.p.A. | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| A Study of IMC-A12 in Advanced Solid Tumors | NCT01007032 | Tumors | Cixutumumab | 20 Years - | Eli Lilly and Company | |
| Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | NCT01242943 | Patients With C... | 131I-L19SIP Rad... | 18 Years - 75 Years | Philogen S.p.A. | |
| EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | NCT00006436 | Lymphoma, AIDS-... Lymphoma, Large... | Rituximab Filgrastim EPOCH | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
